Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. epiorgabolism

EPIORGABOLISM SIGNED

Diabetic nephropathy modelling in hESC-derived 3D kidney organoids

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIORGABOLISM project word cloud

Explore the words cloud of the EPIORGABOLISM project. It provides you a very rough idea of what is the project "EPIORGABOLISM" about.

stages    dna    structural    dn    metabolism    pathology    status    blood    hypothesize    aberrant    regeneration    promoters    mainly    vitro    engineered    progression    expertise    patients    impediments    stem    drug    physiological    kidney    promoted    links    model    esrd    lack    methylation    serve    montserrat    genes    encoding    fatty    somatic    enzymes    vivo    pressure    acid    reprogramming    stop    dr    kptcs    signature    epithelial    glycaemic    preclinical    diabetes    genetic    fibrosis    mimic    cas9    date    drugs    regulators    differentiation    acting    reprograming    good    proximal    evidences    hesc    therapies    nephropathy    tool    alterations    treatment    cell    tubular    renal    background    validated    epigenetic    metabolic    crispr    functional    embryonic    occurring    therapy    tissue    molecular    cells    enhancers    disease    oxidation    recapitulate    gained    epigenome    discovery    models    organoids    elucidate    architecture    therapeutic    stage    human    chemistry    ing    diabetic   

Project "EPIORGABOLISM" data sheet

The following table provides information about the project.

Coordinator		 FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA 

Organization address
address: CARRER BALDIRI REIXAC PLANTA 2A 10-12
city: BARCELONA
postcode: 8028
website: http://www.ibecbarcelona.eu

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-04-18   to  2021-08-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

Diabetic Nephropathy is the leading cause of end-stage renal disease (ESRD). To date, treatment of DN is mainly based on drugs acting on glycaemic and blood pressure control, as there is no validated therapy able to stop the progression towards renal failure. One of the main impediments for developing new therapies for DN has been the lack of a good preclinical model which can recapitulate important functional, structural, and molecular features of advanced human diabetic kidney disease. Here, we aim to develop a DN modelling using human Embryonic Stem Cell (hESC) derived kidney organoids which can recapitulate the in vivo architecture, functionality, and genetic signature of DN. Due to the increasing evidences that links aberrant DNA methylation with kidney fibrosis and metabolic reprograming in DN, we hypothesize that early DN progression is promoted by the metabolic alterations occurring in diabetic patients, resulting in the epigenetic reprogramming of kidney proximal tubular epithelial cells (KPTCs). Based in my background in the fields of metabolism and diabetes, together with the expertise of Dr. Montserrat in the field of somatic reprograming, DN and tissue regeneration/differentiation, this proposal seeks to:1) Elucidate the methylation status of the promoters/enhancers of genes encoding enzymes and regulators of fibrosis and fatty acid oxidation in proximal tubular cells obtained from diabetic patients at different stages of DN progression 2) Establish two in vitro models using hESC-derived kidney organoids; an engineered DN in vitro model, using CRISPR Cas9 to mimic the epigenome signature of DN patients and a physiological DN in vitro model which mimic the diabetic physiological chemistry. The information gained from this DN modelling will offer improved insight into disease pathology and progression. Moreover, it may also serve as a tool for drug discovery to identify therapeutic targets for DN.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIORGABOLISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIORGABOLISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

SSHelectPhagy (2019)

Regulation of Selective autophagy by sulfide through persulfidation of protein targets.

Read More  

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

CRAS (2019)

Climate change and Resilience of Agricultural System: an econometric and computational analysis

Read More